ARTICLE | Financial News

AAT deficiency newco Apic Bio launches

August 22, 2017 10:44 PM UTC

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Tuesday with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency.

The company said its lead AAT deficiency candidate, APB-101, has achieved preclinical proof of concept with efficacy shown in vitro and in vivo, and is currently undergoing preclinical toxicology studies in non-human primates...

BCIQ Company Profiles

Apic Bio Inc.